Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 83 results for viral infections

  1. Maribavir for treating refractory cytomegalovirus infection after transplant (TA860)

    Evidence-based recommendations on maribavir (Livtencity) for cytomegalovirus infection in adults after transplant.

  2. HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

    This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.

  3. Interim process and methods for developing rapid guidelines on COVID-19 (PMG35)

    This information sets out the process and methods used to develop rapid guidelines on COVID-19.

  4. C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

    Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

  5. Donor milk banks: service operation (CG93)

    This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

  6. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

  7. Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)

    This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.

  8. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (TA199)

    Evidence-based recommendations on etanercept (Enbrel), infliximab (Remicade) and adalimumab (Humira) for treating active and progressive psoriatic arthritis in adults.

  9. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

  10. Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

    Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.

  11. Elbasvir–grazoprevir for treating chronic hepatitis C (TA413)

    Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C in adults.

  12. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  13. Rapid tests for group A streptococcal infections in people with a sore throat (DG38)

    Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat

  14. Extracorporeal albumin dialysis for acute liver failure (IPG316)

    Evidence-based recommendations on extracorporeal albumin dialysis for acute liver failure. This involves using a dialysis machine to remove both water-soluble toxins and toxins that are attached to albumin and accumulate in liver failure.

  15. Colli-Pee for first void urine collection (MIB273)

    NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .